Viral Hepatitis Prevention and Control

$201.7 Million committed in FY2018–FY2026

Agency: Centers for Disease Control and Prevention, Health and Human Services, Department of
Assistance: Cooperative Agreements
CFDA number: 93.270
What it does: Program activities support integrated viral hepatitis surveillance and prevention programs in states and large cities in the United States. Key strategies include viral hepatitis outbreak planning and response; and surveillance for acute hepatitis A, B and C, and chronic hepatitis C. Partners should develop a jurisdictional viral hepatitis elimination plan, increase comprehensive hepatitis B and C reporting, improve HBV and HCV testing and increase healthcare providers trained to treat hepatitis B and C. Contingent on funding, the following activities can be supported: surveillance for chronic hepatitis B and perinatal hepatitis C; increased hepatitis B and C testing and referral to care in high-impact settings (syringe services programs (SSPs), substance use disorder (SUD) treatment centers, correctional facilities, emergency departments and sexually transmitted disease clinics; and increased access to services preventing viral hepatitis and other infections among persons who inject drugs (PWID). Contingent on funding, an optional component will support improved access to prevention, diagnosis, and treatment of viral, bacterial and fungal infections related to drug use in settings disproportionately affected by drug use. Expected outcomes include improved surveillance for viral hepatitis, increased stakeholder engagement in viral hepatitis elimination planning, and improved access to viral hepatitis prevention, diagnosis, and treatment among populations most at risk.
Who benefits: The general public will benefit from the objectives of this program as well society from the savings realized from treating those that are infected with viral hepatitis.
Who applies: Applicants include State or local governments or their Bona Fide Agents, public and private nonprofit organizations, for profit organizations, small, minority, women-owned businesses, universities, colleges, research institutions, hospitals, community-based organizations, faith based organizations, Federally recognized Indian tribal governments, Indian tribes, and Indian tribal organizations. Additional guidance may be provided in individual program announcements. In addition, funds may be used for costs associated with establishing and maintaining a prevention and control program directed towards prevention of viral hepatitis infections and their manifestations. Recipients may only expend funds for reasonable policies, systems and program purposes including personnel, travel, supplies and services, such as reducing transmission of HAV, HBV and HCV, preventing and delaying the progress of chronic infection, as well as educating and training of the general public and health care providers. Recipients may not use funds for clinical care. Recipients may not generally use funding for the purchase of furniture or equipment. Any such proposed spending must be identified in the budget. The recipient must perform a substantial role in carrying out project objectives and not merely serve as a conduit for an award in another party or provider who is eligible.

Committed by fiscal year

* FY2026 is year-to-date — the fiscal year is still in progress, so its total is still filling in. The striped band and dashed line mark that provisional stretch.

Top recipients

By dollars committed.

How to read these numbers

Committed through this program: Money committed under this assistance listing (its CFDA program), counted in the year each action happened.
How it's paid: Most programs pay out one way — a grant, or a direct payment to individuals; the flow bar only appears when a program genuinely mixes types.
Some recipients aren't itemized: For entitlement programs like Social Security and Medicare, the government reports one aggregate instead of naming tens of millions of people, so the recipient roster isn't part of the public record.
Awards, counted once: An award count is the number of distinct awards with at least one action that year — each counted once, however many times it was amended.
The colored bars: Every bar on this page splits by how the money moves:
Direct payments

Source

USAspending.gov ↗

Viral Hepatitis Prevention and Control

$201.7 Million committed in FY2018–FY2026

Agency: Centers for Disease Control and Prevention, Health and Human Services, Department of
Assistance: Cooperative Agreements
CFDA number: 93.270
What it does: Program activities support integrated viral hepatitis surveillance and prevention programs in states and large cities in the United States. Key strategies include viral hepatitis outbreak planning and response; and surveillance for acute hepatitis A, B and C, and chronic hepatitis C. Partners should develop a jurisdictional viral hepatitis elimination plan, increase comprehensive hepatitis B and C reporting, improve HBV and HCV testing and increase healthcare providers trained to treat hepatitis B and C. Contingent on funding, the following activities can be supported: surveillance for chronic hepatitis B and perinatal hepatitis C; increased hepatitis B and C testing and referral to care in high-impact settings (syringe services programs (SSPs), substance use disorder (SUD) treatment centers, correctional facilities, emergency departments and sexually transmitted disease clinics; and increased access to services preventing viral hepatitis and other infections among persons who inject drugs (PWID). Contingent on funding, an optional component will support improved access to prevention, diagnosis, and treatment of viral, bacterial and fungal infections related to drug use in settings disproportionately affected by drug use. Expected outcomes include improved surveillance for viral hepatitis, increased stakeholder engagement in viral hepatitis elimination planning, and improved access to viral hepatitis prevention, diagnosis, and treatment among populations most at risk.
Who benefits: The general public will benefit from the objectives of this program as well society from the savings realized from treating those that are infected with viral hepatitis.
Who applies: Applicants include State or local governments or their Bona Fide Agents, public and private nonprofit organizations, for profit organizations, small, minority, women-owned businesses, universities, colleges, research institutions, hospitals, community-based organizations, faith based organizations, Federally recognized Indian tribal governments, Indian tribes, and Indian tribal organizations. Additional guidance may be provided in individual program announcements. In addition, funds may be used for costs associated with establishing and maintaining a prevention and control program directed towards prevention of viral hepatitis infections and their manifestations. Recipients may only expend funds for reasonable policies, systems and program purposes including personnel, travel, supplies and services, such as reducing transmission of HAV, HBV and HCV, preventing and delaying the progress of chronic infection, as well as educating and training of the general public and health care providers. Recipients may not use funds for clinical care. Recipients may not generally use funding for the purchase of furniture or equipment. Any such proposed spending must be identified in the budget. The recipient must perform a substantial role in carrying out project objectives and not merely serve as a conduit for an award in another party or provider who is eligible.